Dr. Daniel Billadeau
Dr. Daniel Billadeau is Professor and Chair of the Department of Immunology, and Deputy Director for Basic Science in the Mayo Clinic Comprehensive Cancer Center. Dr. Billadeau obtained his graduate degree from the University of Minnesota and did his postdoctoral training in molecular immunology/biochemistry before beginning his independent research career in the Division of Oncology Research at Mayo Clinic. Dr. Billadeau’s research efforts have focused on identifying molecular targets in pancreatic ductal adenocarcinoma (PDAC). His group was the first to demonstrate that glycogen synthase kinase-3β (GSK-3b) is overexpressed and localized to the nucleus in PDAC where it regulates tumor cell survival and chemoresistance. His group is actively engaged in understanding the role of GSK-3b in tumor development in vivo and is working toward defining mechanisms of resistance to elraglusib.